Notably, RT plus Y332D markedly enhanced the infiltration of CXCR3+ T, CXCR3+ CD8+ T, CXCR3+ CD4+ T, and CXCR3+ NK cells versus either monotherapies or vehicle (Figure 6e–g), potentially due to the recruitment of CXCR3‐positive lymphocytes into the tumor by CXCL10 secreted by tumor cells, which is promoted by RT. This evidence concerns the gene CD8A and neoplasm.